

FOR IMMEDIATE RELEASE



Contact: <i>Teo Forcht Dagi</i> HLM Venture Partners (617) 896-4234 tdagi@hlmvp.com	<i>Katherine McMillan</i> Compton Consulting Group (617) 451-2035 katherine@comptonconsulting.com	<i>Gary H. Stroy, CEO</i> IntelliDx, Inc. (650) 704-8927 gstroy@intellidx.com
---	---	--

HLM Venture Partners Co-Leads \$21.5 million Financing for IntelliDx

Boston, MA, March 19, 2008 - HLM Venture Partners, a Boston and San Francisco-based health care venture capital firm, announced that it has made a \$6.5 million investment in IntelliDx, Inc. of Santa Clara, CA. The investment is part of a \$21.5 million Series D Preferred stock financing that was co-led by HLM and 3i Ventures.

IntelliDx is a development stage medical device company focused on the commercialization of an automated point-of-care blood analyzer for use in hospital intensive care units (ICU). The device, called OPTIMUS®, uses well-established electrochemical sensor technology and is first being applied to automate the measurement of blood glucose levels in the many ICU patients with hyperglycemia. Patients with sustained high blood glucose levels are at a high risk of developing other complications and their length of hospital stay is often prolonged. Intravenous insulin drip therapy used to control this serious condition and hourly glucose measurements are required to fine-tune the insulin dosage. This testing is currently done manually at the bedside or by central laboratories at considerable expense and interference with the normal workflow.

HLM partner, Teo Forcht Dagi, who has joined IntelliDx's board of directors, commented: "Our team has been actively searching for several years for a company that automates blood analysis at the point-of-care, a potentially revolutionary development in medicine which physicians have been seeking for many years. This need has become

increasingly acute with the more recent recognition of the frequency of stress-hyperglycemia in the ICU. We believe IntelliDx offers an effective and cost-efficient mechanism to relieve the strain on nursing staff and will be the first-to-market in this large new monitoring segment.”

Gary Stroy, President and CEO of IntelliDx, added: “As we move forward with the commercialization of this process, we are fortunate to have investors such as HLM and 3i who have not only a broad understanding of the health care industry, but also specific knowledge of medical devices and their particular application.” Prior to joining IntelliDx in June 2007, Gary founded seven medical device companies. He is well-known as a pioneer in the commercialization of many point-of-care diagnostic technologies and products as the founder of LifeScan (sold to J&J), Biotrack, ChemTrak, and Abaxis.

Ephraim Heller, IntelliDx Chairman, said of the stock financing: “We are especially pleased to have both new and existing investors participate in this fund-raising effort. We also appreciate the spirit of partnership that our investors bring to the company as it continues this major development effort.”

Joining HLM and 3i Ventures in the Series D financing are existing investors Giza Ventures, Ascend Ventures, and Aurum Ventures as well as new investors Sequel Venture Partners and Hunt BioVentures.

About IntelliDx, Inc. IntelliDx is a development stage medical device company located in Santa Clara, California. The Company is developing a point-of-care blood analyzer for use in critical areas of hospitals that can automatically sample micro-quantities of whole blood from a patient’s intravenous line and perform frequent measurements of various blood constituents. The device operates unattended and can report test measurements at programmed intervals to a hospital’s information system around-the-clock. The company expects to launch its product in mid-2009.

About HLM Venture Partners HLM Venture Partners provides venture capital to emerging companies focused on health care information technology, health care services and medical technology. During the past 15 years, HLM has helped more than 60 privately-held health care companies turn innovative ideas into market-leading businesses. The company’s investment professionals have over 125 years of collective

expertise in the health care industry, an accumulation of knowledge and experience that is invaluable to the leadership of its portfolio companies. For more information, visit:

www.hlmventurepartners.com

-ends-